XML 47 R29.htm IDEA: XBRL DOCUMENT v3.22.1

Note 3 - Research and Collaboration Agreements, Sublicense Agreements and Investments in Privately Held Companies (Details Textual)				1 Months Ended	12 Months Ended
	Jun. 24, 2020	Jun. 30, 2017 USD ($)	Jun. 30, 2017 EUR (€)	Aug. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 16, 2021 USD ($)	Dec. 16, 2021 EUR (€)	Jul. 26, 2021	Jul. 08, 2021 shares	Dec. 01, 2020	Apr. 26, 2019
Upfront Payment Payable							$ 500,000
Research and Development Expense, Related Party					$ 0
Number of Performance Obligations							2	2
Cost of Goods and Services Sold, Total					1,944,438	$ 1,424,931
Accounts Receivable, after Allowance for Credit Loss, Current, Total					277,831	294,199
Collaborative Arrangement, Payment for Research and Development Agreement		$ 1,100,000	€ 1,000,000.0
BDI Holdings [Member]
Proceeds from Sales of Business, Affiliate and Productive Assets				$ 1,600,000	1,600,000
Research Services Agreement [Member]
Collaborative Arrangement, Payment for Research and Development Agreement | €			€ 1
Alphazyme [Member]
Sale of Stock, Percentage of Ownership after Transaction	2.50%
Equity Securities without Readily Determinable Fair Value, Amount						284,709
Novovet [Member]
Equity Method Investment, Ownership Percentage												20.00%
Unbilled Revenues [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total					176,656	$ 163,667
ID Biologics Inc [Member]
Investment Owned, Balance, Shares (in shares) | shares										129,661
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners										0.37%
Alphazyme [Member]
Ownership Percentage											1.99%
BDI Holdings [Member]
Ownership Percentage									16.10%
BDI Holdings [Member] | Research Services Agreement [Member]
Collaborative Arrangement, Equity Interest Acquired		16.10%	16.10%
Collaborative Arrangement, Minimum Obligation For Research and Development		$ 936,000
VLPBio Member
Ownership Percentage									3.30%
VLPBio Member | Research Services Agreement [Member]
Collaborative Arrangement, Equity Interest Acquired		3.30%	3.30%
Janssen Pharmaceutical Companies [Member]
Non-refundable Upfront Payment, Received							$ 500,000
Deferred License Revenue					500,000
ID Biologics Inc [Member]
Cost of Goods and Services Sold, Total					194,000
ID Biologics Inc [Member] | Unbilled Revenues [Member]
Accounts Receivable, after Allowance for Credit Loss, Current, Total					$ 27,000
Research and Development [Member] | Janssen Pharmaceutical Companies [Member]
Contract with Customer, Asset, after Allowance for Credit Loss, Total | €								€ 1,600,000

X

- Definition

Represents equity interest acquired for collaborative agreement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix:	dyai_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents minimum obligation for research and development for collaborative agreement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents payment for research and development agreement for collaborate arrangement.

+ References

No definition available.

+ Details

Name:	dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents deferred license revenue.

+ References

No definition available.

+ Details

Name:	dyai_DeferredLicenseRevenue
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents ownership percentage by noncontrolling owners for noncontrolling interest.

+ References

No definition available.

+ Details

Name:	dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	dyai_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Represents non-refundable upfront payment, received.

+ References

No definition available.

+ Details

Name:	dyai_NonrefundableUpfrontPaymentReceived
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents number of performance obligations.

+ References

No definition available.

+ Details

Name:	dyai_NumberOfPerformanceObligations
Namespace Prefix:	dyai_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Percentage of ownership.

+ References

No definition available.

+ Details

Name:	dyai_OwnershipPercentage
Namespace Prefix:	dyai_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Represents the amount of related-party research and development expense recognized during the period.

+ References

No definition available.

+ Details

Name:	dyai_ResearchAndDevelopmentExpenseRelatedParty
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Represents upfront payment payable.

+ References

No definition available.

+ Details

Name:	dyai_UpfrontPaymentPayable
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522

+ Details

Name:	us-gaap_AccountsReceivableNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044

+ Details

Name:	us-gaap_ContractWithCustomerAssetNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Amount of investment in equity security without readily determinable fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714

+ Details

Name:	us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Balance held at close of period in number of shares.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 50
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B))
-URI http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010

+ Details

Name:	us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dyai_BDIHoldingsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_OwnershipAxis=dyai_IDBiologicsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_OwnershipAxis=dyai_AlphazymeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_OwnershipAxis=dyai_VLPBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=dyai_JanssenPharmaceuticalCompaniesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=dyai_IDBiologicsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: